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Abstract
Background: Spasticity is one of the problems after a stroke. Due to this increase in muscle tone, patients are
confronted with problems in motor control and difficulties in activities of daily living and complications such as
shortness and contracture. The aim of this study was to examine the effects of the simultaneous use of both
splint and botulinum toxin-A (BTX-A) injection on spasticity, range of motion and upper extremity function in a
3-month period.
Methods: In this study a comparison was done between three groups of interventions, conducted in rehabilita-
tion clinics in Tehran. Sixty people with chronic stroke were recruited. Based on the inclusion criteria, a total of
39 stroke patients after completing the consent forms were entered to intervention groups; splint or botulinum
toxin injection or combined splint/botulinum toxin injection. They were followed up about three months and the
evaluations were done monthly. Goniometry was the method to measure the range of motion, and Modified
Ashworth Scale was used to examine the spasticity and the upper extremity function was scored based on Fugl-
Meyer Assessment.   Statistical analysis was done using SPSS 17. And ANOVAs was used for comparison be-
tween groups and times.  Significance was set at 0.05.
Results: All outcome measures were improved within each group but the differences between splint group and
BTX-A group and the BTX-A-splint group was not significant in most outcomes during the 3 periods (first
evaluation until end of the first month, the end of first month until the end of second month, the end of second
month until the end of the third month) (p>0.05). The results also showed that the changes in elbow`s spasticity
(p=0.05) and wrist`s spasticity (p=0.007) and upper extremity function (p=0.04) were obvious between the three
groups over the 3-months and the difference in the group of combined use of botulinum toxin, and the splint was
more than other groups.
Conclusion: In this study, the effects of botulinum toxin injection and Volar-Dorsal Wrist/Hand Immobiliza-
tion splint and the combined use of botulinum injection and splint were obvious in all groups but was not signif-
icantly different between the interventions in a 3-month follow-up.
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Introduction
Annually, 15 million people worldwide
suffer a stroke. Of these, 5 million dies and
another 5 million are left permanently
disabled, placing a burden on family and
community (1). The epidemiology of stroke
and its subtypes in the Middle East is un-
clear. A study provided evidence that the
incidence of stroke in Iran is considerably
greater than in most Western countries,
with stroke occurring at younger ages
around 45 years old. Ischemic stroke inci-
dence was also considerably greater than
reported in other regions (2). Stroke is a
common cause of disability. One of the
complications after a cerebrovascular acci-
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dent is spasticity or muscle hyper-tonicity
that is determined with an increase in
speed-dependent resistance against passive
tension and the intensive stretch reflexes.
After a stroke, due to the rise of muscle
tone, increased reflex activity and reduced
inhibitory control, patients are confronted
with problems in motor control and this
problem also lead to difficulties in activities
of daily living and complications such as
shortness and contracture (3). The most re-
covery of neuromuscular system may occur
within the six months after the accident.
Long-term recovery period of these sys-
tems may be associated with problems such
as spasticity, rigidity, and defects in motor
functions such as synkinesis (involuntary
movements in other parts, while moving
another extremity). Neurolysis, denervation
with chemicals and casting techniques are
considered as treatment methods to resolve
these complications (3,4). Alongside cur-
rent spasticity preventions such as stretch,
exercise, and positioning, treatment options
include oral anti-spasm drugs, blocking by
phenol, baclofen and botulinum toxin local
injections (5). Oral antispasmodic medica-
tions often have limited and short-term ef-
fects and result in complications such as
weakness, dizziness and dry mouth (6,7).
Neurolysis by injecting phenol or alcohol
effectively reduces spasticity (8,9), but is
followed by severe pain, And the invasive
method of intrathecal baclofen injection
besides good results leads to severe reac-
tions such as nausea, vomiting and head-
ache(10,11). Botulinum Toxin as a degen-
erative chemical drug with reversible clini-
cal effects is another way to reduce muscle
spasticity in stroke patients. Botulinum
Toxin causes a neuromuscular block in ace-
tylcholine release, thereby preventing neu-
romuscular transmission and muscle con-
traction and many studies have reported the
effects of this drug on spasticity (12-16).
And various papers have reported different
results. Hesse, Bhakta and their colleagues
studied the impact of botulinum toxin on
spasticity and concluded that the injection
of botulinum toxin is a safe and effective
method for reducing disability in spastic
patients (17,18). Also, splints are therapeu-
tic devices discussed to prevent contracture
and spasm progression; it has been reported
any bad application of splint can cause de-
formity and may worsen the spasm (19,20).
Therefore, the proper use and wearing of
splint by the patients should be checked by
a therapist (19). Two groups of orthoses for
the treatment of spasticity are: 1 - progres-
sive orthoses: that is applied to improve the
range of motion in affected joints by in-
creasing the amount of slow stretch created
in the joint. This orthosis can be used to
modify or prevent spasm, particularly if the
spasm remains after injection of botulinum
toxin. 2 - Serial orthoses: work as progres-
sive orthoses but the difference is, they are
prescribed as a brace, which gradually in-
crease the range of motion (19). In this
study, we used a type called volar-dorsal
static (immobilization) splint that works
through the application of serial static force
(19). Because of the specific structure of
this splint, the patient is able to touch ob-
jects on the palm, and this is considered as
an advantage over other splints.
Since the use of splint and injections of
botulinum toxin have their particular costs
for many families, thus efficiency and
comparison of these interventions are
important to resolve patient`s problems.
Hill in 1994, in an article, explained that
the method of extremity casting was more
effective than conventional methods such
as passive range of motion exercises, static
stretching and splinting (21). But another
study by Cusick, Novak, and Lannin in
2007, has been reported different results
such as weakness due to immobilization
condition in the casting method (22). And
finally, most of the studies didn’t show ac-
curate effects of splints in reducing spas-
ticity because of methodological limitations
such as lack of inappropriate assessment
and lack of control groups. Lai and col-
leagues in 2009 studied the effects of botu-
linum toxin Injection accompanied by Oc-
cupational Therapy, and also examined the
use of a dynamic splint along with those
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two interventions and reported contracture
reduction and range of motion improve-
ment (23). We didn’t find any study about
the effect of the Volar-Dorsal splint on
hand function and the comparison of the
effect of splint and BTX-A. So, In this
study, through monthly clinical evaluations,
the efficacy of BTX-A  drug, splinting and
BTX-A with splinting were examined to
result possibly in the use of these findings
in clinics and subsequent research studies.
Methods
Participants
This study has been done in three groups
as pretest-posttest design in rehabilitation
clinics in Tehran.  Sixty patients with
chronic stroke were selected by a non-
randomized simple method. According to
the inclusion criteria, a total of 39 stroke
patients after completing the consent forms
entered to the study into three groups in-
cluding putting the splint, BTX-A injection
and combined splinting and BTX-A injec-
tion groups. Of these, 29 patients complet-
ed the study. Thirty patients participated till
the end of the second month, and nine pa-
tients were missed due to discordance and
absence in the assessment sessions. Also
one patient died from a second stroke just
before the final assessment.
Procedure
Inclusion criteria for the study were: at
least a year passed since the last stroke, age
between 20 to 64 yrs, score above 22 on the
cognitive test of Mini-Mental Status Exam
(MMSE), no other neurological diseases,
having a maximum spasticity score of 3 on
the Modified Ashworth scale (MAS), the
ability to sit at least 10 minutes
independently on the edge of the bed, and
not receiving botulinum toxin or similar
splints while entering the study. If any of
the patients had the following situations,
he/she would be excluded from the re-
search: occurrence of orthopedic lesions in
the upper extremity, occurrence of any oth-
er neurological disease, absence in posttest
evaluation. To make this kind of splint,
initially, positive patterns were made in two
sizes of men and women for the left or right
hand. Then, all splints were fabricated
based on the patterns. Splints immobilized
the wrist in 10 degrees of extension, thumb
in hyper-abduction and fingers in zero, so
the angles of splint were the same for all
patients. The complete initial data were
gathered and recorded. Afterward, the pa-
tients received BTX-A injections, splints or
splint-BTX-A for three months. In this
work, Volar-Dorsal Wrist/Hand Immobili-
zation splint and BTX-A was surveyed.
Dosage for each muscle was 50-150 IV
based on the bulk of muscles (FCR, FCU,
Pronator Teres, FDP, FDS, FPL, and Pal-
maris Longus). Patients in the splint and
splint-BTX-A group were clarified to wear
these splints 2 hours a day and all the night
(6 to 8 hours) about 3 months. Re-
evaluation for three groups was performed
at the end of each month. At the end of the
first month 31 patients (11; splint – 11;
botulinum toxin   9; splint-BTX-A) and fi-
nally at the end of the third month, 29 pa-
tients (9; splint – 11; botulinum toxin and 9
splint-BTX-A) were present for the as-
sessment. In this 3-month period patients
were called and reminded to use the splint.
It should be noted that all patients were also
participating in a routine Occupational
Therapy program three times a week during
the study.
Outcome Measure
Before the initiation of the interventions
(splinting, botulinum toxin injection or
splint-botulinum toxin.) active and passive
range of motion of elbow, wrist and
metacarpophalangeal joints were assessed.
Other outcome measures were elbow and
wrist spasticity and upper extremity func-
tion. Goniometry was the method to meas-
ure the range of motion, and Modified
Ashworth Scale was used to examine the
spasticity, and the upper extremity function
was scored based on Fugl-Meyer Assess-
ment.
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Statistical Analysis
We calculated the descriptive and analytic
statistics using SPSS 17. To investigate
whether one of the groups changed more
than the other group at the end of 1st, 2nd
and 3rd month, we calculated the change of
scores (changes in the scores of each
variable in each month) for each group. We
compared them using One Way ANOVA,
and Tukey method was used as post-Hoc
multiple comparisons. We also used
analyzes of variance (ANOVAs) with re-
peated measures with a between-subject
factor at three levels (3 groups) and a with-
in-subject factor at four levels (time:
baseline, 1st month, 2st month, 3rd month).
The interaction of group and time served to
determine the efficacy of the each therapy
on the outcome measures. Significance was
set at 0.05.
Results
The mean age of the patients was 49.90
yrs in drug injection group, 52.55 yrs in the
splint group and 54.32 yrs in Botox-splint
group .The average time passed since a
stroke in the botulinum toxin injection
group was 28.81 months, 29.22 months in
the splint group and 26.22 months in Bo-
tox-splint group. Mean cognitive scores
(MMSE) was 25.81 in the injection group,
27.44 in the splint group and 27.22 in Bo-
tox-splint group (Table 1).
According to Table 2, results of the active
range of elbow in the second month was
significant (0.02) and Tukey test showed
that this difference was due to the differ-
ence between BTX-A and splint group.
And the changes in scores of other varia-
bles were not significant between groups
(Table 2).
Table 3 presents the motor recovery,
spasticity and range of motion of patients at
baseline, end of first, and two and the end
of the third month. According to the results
contained in Table 3, all variables in both
groups have been improved to some extent,
but just the difference between three groups
was significant in Fugl-Meyer Assessment
(FMA), Elbow MAS And Wrist MAS out-
come. And differences between three
groups in other variables was not signifi-
cant (Table 3).
Discussion
Results of this study showed that after 3
months of Volar-Dorsal Wrist/Hand
Immobilization splint, Botulinum toxin
injection, and simultaneous use of these
two interventions, all variables have
improved but the difference between three
groups in a 3 period (time sequence) (first
evaluation until end of the first month, the
end of the first month until the end of the
second month, the end of the second month
until the end of the third month) was not
significant in most outcomes. Reason for
this lack of meaningfulness can be the low
sample size. To get better results, more
samples may be needed in the hope that
future studies will pursue this issue.
Changes in severity of spasticity in these
three periods (first evaluation until the end
of the first month, the end of the first month
until the end of the second month, the end
of the second month until the end of the
third month) were not significant between
groups. This may be due to low reliability
and low sensitivity of MAS (24). Perhaps
because MAS evaluates thixotropy and
fixed muscle contracture in addition to
spasticity, this test is incompetence. It
seems electrophysiological assessments
like Hmax/Mmax tests are good criterion
for measuring spasticity. A study in 2005
by Pizzi and colleagues have shown that
Table1. The characteristics of three study groups
Variable Botox (n=11) Splint (n=9) Botox-splint (n=9)
Age (y)
Sex (women/men)
Time since stroke (m)
Mean MMSE
Side (right/left)
49.9±10.84
7/4
28.8±22.97
25.8±3.60
6/5
52.5±10.41
4/5
29.2±13.90
27.4±2.69
5/4
54.3±8.97
4/5
26.2±23.53
27.2±2.94
2./7
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using a volar splint about three months re-
duced spasticity and this improvement was
only seen with neurophysiological tests,
and the MAS results were not significant
(25). The data in Table 3 shows that either
at the end of the first month or the end of
second and the third months, the impact on
wrist spasticity was significantly different
between groups and the changes in a group
of combined use of Botulinum toxin injec-
tion and splint were more than other
groups, respectively. Also according to the
results contained in Table 2 and 3, the level
of spasticity in each group has decreased.
Spasticity Reduction in the Botox splint
group has been more than two other groups.
It is presented that trend of spasticity
reduction in the splint group has been con-
stant during three months of study. But
botulinum toxin injection trend has been a
different process so that at first there was a
period of a great reduction in the severity of
Table 2. Between-group differences in change scores for spasticity, active/passive range of motion and function
2 nd to 3rd Month1 st to 2 nd MonthBaseline to1 st Month
pBotox-
splint
group
Splint
group
Botox
group
pBotox-
splint
group
Splint
group
Botox
group
pBotox-
splint
group
Splint
group
Botox
group
Parameter
0.200.3310.090.73-0.1100.180.810.550.330.27Elbow MAS*
0.3000-0.450.700.110-0.180.0610.221.09Wrist MAS
0.98-5.66-8.75-5.630.029.3320-170.40-13.88-55.63Elbow AROM*
0.30-0.5501.810.167.220-1.810.60-5-1.66-.90Elbow PROM*
0.60-2.551.25-9.270.47-14.77-1.753.630.90-5.44-3.66-1.90Wrist AROM
0.90-3.33-3.75-1.360.40-4.447.5-100.90-9.44-10-7.27Wrist PROM
0.300.334.5-20.55-1.11-3.75-5.270.15-23.88-4.77MP* AROM
0.07-0.55-52.720.201.112.5-2.720.208.88-2.22-1.36MP PROM
0.70-2.33-3.25-4.720.20-2.441.25-2.180.42-9.88-2.11-2.09FMA*
*MAS: Modified Ashworth Scale, AROM: Active Range of Motion, PROM: Passive Range of Motion, MP:MetacarpoPhalengeal, FMA: Fugl-Meyer
Assessment
Table 3. Motor Recovery, Spasticity, and Passive/Active Range Of Motion Scores of Patients at Baseline, 1st Month, 2st Month and
3rd Month
p*Δ(95٪)3st Month2nd Month1st MonthpretreatmentGroup
0.050.54(0.08 , 1.007)
0.77(0.43 , 1.11)
0.77(0.03 , 1.52)
1.4
0.77
1.55
1.5
1.7
1.8
1.7
1.2
1.7
2
1.5
2.3
Botox
Splint
Botox-splint
Elbow MAS
0.010.45(-0.24 , 1.15)
0.44(-0.23 , 1.12)
1.14(0.39 , 1.82)
2.4
2.3
1.4
2
3.2
2.44
1.8
2.5
2.5
2.9
2.7
3.5
Botox
Splint
Botox-splint
Wrist MAS
0.50-17.72(-55.51 , 20.06)
2.7(-25.14 , 30.69)
-10.22(-37.94 ,7.77)
77.45
81.66
69.66
71.8
68.75
64
54.9
89.44
73.33
59.7
84.4
59.4
Botox
Splint
Botox-splint
Elbow AROM
0.50-0.9(-3.43 , 1.61)
-1.6(-5.96 , 2.63)
1.6(-17.64 , 20.97)
1.35
1.35
1.27
1.36
1.35
1.27
1.35
1.35
1.34
1.34
1.33
1.29
Botox
Splint
Botox-splint
Elbow PROM
0.30-7.54(-17.51 , 2.42)
-6(-16.13 , 4.13)
-22.77(-62.25, 16.7)
24.09
13.22
42.22
14.81
13.75
39.66
18.45
10.88
24.88
16.54
7.22
19.44
Botox
Splint
Botox-splint
Wrist AROM
0.40-18.63(-36.91 , -0.35)
-17.22(-37.29 , 2.85)
-17.22(-78.32 , 43.88)
1.72
1.55
1.44
1.71
1.45
1.41
1.61
1.47
1.36
1.54
1.37
1.27
Botox
Splint
Botox-splint
Wrist PROM
0.18-3.36(-8.96 , 2.23)
-7.22(-12.54 , -1.89)
-24.66(-66.78 , 17.45)
14.27
9.66
30.77
12.72
10
31.11
7.45
7.22
30
11.36
2.44
6.11
Botox
Splint
Botox-splint
MP AROM
0.47-1.36(-4 , 1.27)
-3.33(-11.48 , 4.81)
9.44(-12.33 , 31.22)
94.45
95
80
98.18
88.75
80
95.45
93.88
81.11
94.09
91.66
90
Botox
Splint
Botox-splint
MP PROM
0.04-9(-15.87 , -2.21)
-4.66(-9.95 , 0.61)
-14.66(-33.08 , 3.75)
30.27
27.88
32.88
25.54
19
30.55
23.36
25.33
28.11
21.27
23.22
18.22
Botox
Splint
Botox-splint
FMA
* Δ, mean change at 3rd Month from baseline. ANOVA for repeated measures.
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spasticity and after the first month this out-
come gradually increased again. This could
indicate that effect of botulinum toxin in-
jection on spasticity is temporary. This is-
sue approves the pharmacodynamics prop-
erties of botulinum toxin, which
neurotransmission restores by neural
sprouting process, almost after 3months
(26). So, according to the ascending trend
of spasticity improvement in the combined
treatments group and the splint group and
the unstable trend of spasticity improve-
ment in the group of botulinum toxin injec-
tion, it can be said that perhaps the time (3
months) was not enough to get more defi-
nite results for comparing the interventions
impacts.  We hope that future research will
pursue this issue. Kirazli and colleagues in
1998 concluded that injecting botulinum
toxin into spastic soleus muscles has a
significant reduction in the muscle’s spas-
ticity in the second and fourth weeks, but
this decrease was not seen at the end of
weeks 8 and 12 (27).  But in another study
by Eduardo, the results were different from
our study and spasticity continued to dimin-
ish even up to 32 weeks after injection of
the botulinum toxin and these changes were
significant (28). The results depicted in Ta-
ble 2 show that during the second month
the impact on the range of motion of the
elbow between three interventions is signif-
icantly different. These differences were
calculated using the Tukey test. This level
of significance is because of the large dif-
ference between the mean changes in splint
and BTX-A group. Changes of active and
passive wrist range of motion showed im-
provement in all three groups and in the
Botox - Splint group were more than other
groups. But these changes between groups
were not significantly different in these
times (the first assessment, the first end, the
end of the second month, and the end of the
third month), these results would be as a
result of low sample sizes too. In Wallen`s
study among 4 groups of cerebral palsy
children (botulinum toxin injection,
botulinum toxin injection along with
occupational therapy, occupational therapy,
and control) similar effects on upper
extremity were reported (29). In contrast to
our work, Eduardo reported that range of
motion may improve up to 32 weeks after
injection of the botulinum toxin. The ad-
vantages of that research seem to be an
evaluation of isolated muscles and adjust-
ing injection doses based on the need of
each muscle (28). MP joint`s active range
of motion changes in all three groups had a
little change, and the difference was not
evident between the three groups. Although
the change process in patients who used the
splint was a gradual and continuous
improvement, injection of botulinum toxin
clearly decreased the active range of mo-
tion in the first month that can be caused by
temporary poisoning and weakening effect
of this drug on muscles. This active ROM
reduction was modulated at the third
month, perhaps because of the time passed
and a decrease in drug`s effect. Changes in
passive range of motion of MP joints were
not evident either within or between
groups, and these results were predictable
due to a complete passive range of motion
in most patients at the baseline. Upper ex-
tremity function, as well as other variables,
didn't show a significant difference be-
tween interventions at the end of treatment,
but the trend of changes in all groups
showed significant improvement and the
trend of combined group was better than
two other groups. Obviously, the function
of upper limb is associated with range of
motion and muscle tone, therefore in this
study lack of significant results of the tone
and range of motion in time periods (the
first assessment to the end of the first
month, first month until the end of the se-
cond month, second month until the end of
the third month), insignificant results of
upper limb`s function can be normal. Due
to significant changes in spasticity at
different times (the first assessment, the
end of the first month, the end of the
second month, and the end of the third
month), it was predictable that the results of
upper extremity functions might change
significantly between the three groups at
M. Amini, et al.
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different times (the first assessment, the
end of the first month end second month,
third month and the end) (Table 3). Re-
search in 2000 by Gracise and colleagues
has shown that upper limb function will
improve in certain tasks. Gracise explained
this improvement with regard to the better
perception of the senses and reduced spas-
ticity and increased the range of motion in
some joints of the affected hemiplegic side
as an outcome of using of a Garment (19).
Katz and colleagues in a study showed a
strong correlation between spasticity and
hand function (30). Although the scales
such as the MAS give little clinical infor-
mation with low validity and sensitivity to
changes, they are still being used in many
types of research (24). In a case report by
Shun-fen sun, it was concluded that botuli-
num toxin injection accompanied with any
other treatment such as CIMT, improves
spasticity of upper limb (31). Our results
could confirm the studies of researchers
who have reported that functional effects of
botulinum toxin would be more beneficial
when accompanied by the muscle retrain-
ing and splinting (32).
Conclusion
In this study, the effects of botulinum toxin
injection and Volar-Dorsal Wrist/Hand
Immobilization splint and the combined use
of botulinum injection and splint were not
significantly different between the interven-
tions in a 3-month follow-up.
Limitation
Using the splint by the participants at the
correct time and the low number of strokes
people with our inclusion criteria were the
limitations of this study.
Acknowledgments
The authors would like to thank the
stroke people and their families who kindly
participated in this study.
References
1. World Health Organization [Internet]. Global
burden of stroke. Available from: http://www.
who.int/cardiovascular_diseases/en/cvd_atlas_15_b
urden_stroke.pdf
2. Azarpazhooh MR, Etemadi MM, Donnan GA,
Mokhber N, Majdi MR, Ghayour-Mobarhan M, et
al. Excessive incidence of stroke in Iran: evidence
from the Mashhad Stroke Incidence Study (MSIS),
a population-based study of stroke in the Middle
East. Stroke 2010;41(1):3-10.
3. Starsky AJ, Sangani SG, McGuire JR, Logan B,
Schmit BD. Reliability of Biomechanical spasticity
measurements at the elbow of people post stroke.
Arch Phys Med Rehabil 2005;86(8):1648-54.
4. Hilliard MJ, An K in: Hsu J, Michael JW, Fisk
JR, Editors. Biomechanics of Upper Limbs. AAOS
Atlas of orthoses and Assesstive Devices. Upper
Extemity Orthosis.  4th. Philadelphia. Mosby,
Elsevier. 2008:169-179.
5. Ozcakir S, Sivrioglu K. Botulinum toxin in
poststroke spasticity. Clin Med Res 2007;5(2):132-
8.
6. Gallichio JE. Pharmacologic management of
spasticity following stroke. Phys Ther 2004;84:
973-81.
7. Chou R, Peterson K, Helfand M. Comparative
efficacy and safety of skeletal muscle relaxants for
spasticity and musculoskeletal conditions: a sys-
tematic review. J Pain symptom Manage 2004;28:
140-75.
8. McCrea PH, Eng JJ, Willms R. Phenol reduces
hypertonia and enhances strength: a longitudinal
case study. Neurorehabil neural repair. 2004;
18(2):112-6.
9. Jang SH, Ahn SH, Park SM, Kim SH, Lee KH,
Lee ZI. Alcohol neurolysis of tibial nerve motor
branches to the gastrocnemius muscle to treat ankle
spasticity in patient with hemiplegic stroke. Arch
Phys Med Rehabil 2004;85(3):506-8.
10. Meythaler JM, Guin-Renfroe S, Brunner RC,
Hadly MN. Intrathecal baclofen for spastic hyper-
tonia from stroke. Stroke 2001;32:2099-109.
11. Francisco GE, Boake C. Improvement in
walking speed in post stroke spastic hemiplegia af-
ter intrathecal baclofen therapy: a preliminary
study. Arch Phys Med Rehabil 2003;84:1194-99.
12. Woldag H, Hummelshein H. Is the Reduction
of Spasticity by botulinum toxin a beneficial for the
Recovery of motor function of arm and hand in
stroke patients? Eur Neurol 2003;50:165-71.
13. Wang HC, Hsieh LF, Chi WC, Lou SM. Ef-
fect of intramuscular botulinum toxin injection on
upper limb spasticity in stroke patients. Am J Phys
Med Rehabil 2002;81(4):272-8.
14. Bakheit AM, Thilmann AF, Ward AB, Poewe
W, Wissel J, Benecke R, et al. A randomized, dou-
ble-blind, placebo-controlled, dose-ranging study to
compare the efficacy and safety of three doses of
botulinum toxin type A (Dysport) with placebo in
upper limb spasticity after stroke. Stroke 2000;
Botulinum toxin, splinting and function in stroke patients
8 Med J Islam Repub Iran 2016 (21 May). Vol. 30:373.http://mjiri.iums.ac.ir
31:2404-6.
15. Bakheit AM, Pittock S, Moor AP, Wurker M,
Otto S, Erbguth F, et al. A randomized, double-
blind, placebo-controlled study of  the efficacy and
safety of  botulinum toxin type A in upper limb
spasticity in patients with stroke. Eur J Neurol
2001; 8:559-65.
16. Smith SJ, Ellis E, White S, Moore AP. A dou-
ble-blind placebo-controlled study in botulinum
toxin in upper limb spasticity after stroke or head
injury. Clin Rehabil 2000;14(1):5-13.
17. Bakhta BB, Cozens JA, Bamford JM, Cham-
berlain MA. Use of botulinum toxin in stroke pa-
tients with severe upper limb spasticity. J Neurol
Neurosurg Psychiatry 1996;61(1):30-5.
18. Hess S, Friedrich H, Domasch C. Botulinum
toxin therapy for upper limb flexor spasticity: pre-
liminary results. J Rehab Sci 1992;5:98-101.
19. Gracies JM, Marosszeky JE, Renton R,
Sandanam J, Gandevia SC, Burke D. Short term
effect of dynamic Lycra splints on upper limb in
hemiplegic patients. Arch Phys Med Rehabil 2000:
81:1547-55.
20. Gossman MR, Sahrmann SA. Review of
length-associated change in muscle. Physical Ther-
apy 1982;62:1799-1808.
21. Hill, J. The effects of casting on upper extrem-
ity motor disorders after brain injury. Am J occup
ther 1994;48(3):219-224.
22. Lannin NA, Novak I, Cusick AA. The effects
of splinting on wrist contracture after stroke. Stroke
2007;38:111-116.
23. Lai JM, Gerard E, Francisco F. Dynamic
splinting After Treatment with botulinum Toxin-A:
a randomized controlled pilot study. Adv Ther
2009;26(2):241-248.
24. Starskky AJ, Sangani SG, McGuire JR. Relia-
bility of biomechanical spasticity measurements at
the elbow of people post stroke. Arch Phys Med
Rehabil 2005;86:1648-54.
25. Pizzi A, Carlucci G, Falsini C, Verdesca S,
Grippo A. Application of a Volar static splint in
Post stroke spastisity of upper limb. Arch phys Med
Rehabil 2005;86:1855-9.
26. Paiva A, Meunier FA, Molgó J, Aoki KR,
Dolly JO. Functional repair of motor endplates after
botulinum neurotoxin type A poisoning: biphasic
switch of synaptic activity between nerve sprouts
and their parent terminals. Proc Natl Acad Sci USA
1999;96(6):3200-5.
27. Kirazli Y, On AY, Kismali B, Aksit R. Com-
parison of phenol block and botulinus toxin type A
in treatment of spastic foot after stroke: a random-
ized double blind trial. Am J Phys Med Rehabil
1998;85:902-905.
28. Cardoso E, Pedreira G. Does botulinum toxin
improve the function of the patient with spasticity
after stroke? Arq Neurosiquiatr 2007;65(3-a):592-
595.
29. Wallen M, MA. Functional outcomes of in-
termuscular Botulinum toxin type A and occupa-
tional therapy in the upper limbs of children with
cerebral palsy: A randomized controlled trial. Arch
phys Med Rehabil. 2007;(88):1-10.
30. Katz . RT , Rovai .  GP , Objective quantifica-
tion  of spastic hypertonia: correlation with clinical
findings. . Arch Phys Med  Rehabil,1992.73:339-
47.
31. Sun S-F, Hsu C-W, Hwang C-W. Application
of combined botulinum toxin typeA and Modified
constraint-induced movement therpy for an individ-
ual with chronic Upper-Extremity spasticity After
stroke. Physical therapy.2006(86): 1387-1397.
32. Truman H, Racette W in:Umphred AD, Laza-
no NT, Editors, Orthotics: Evaluation, Intervention
and Prescription. Neurological rehabilitation. 6th
Edition. USA, Mosby, Elsevier . 2013. 1037-1053.
